Arrowhead Pharmaceuticals, Inc. (ARWR) vs Kymera Therapeutics, Inc. (KYMR)
A side-by-side comparison of Arrowhead Pharmaceuticals, Inc. and Kymera Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ARWR
Arrowhead Pharmaceuticals, Inc.
$61.66HealthcareDelayed quote: Oct 6, 2026, 1:30 PM EDT
KYMR
Kymera Therapeutics, Inc.
$104.18HealthcareDelayed quote: Oct 6, 2026, 1:30 PM EDT
Total return — ARWR vs KYMR
growth of $100 · dividends reinvested · last 6yARWR +44.8% (+6.4%/yr)KYMR +230.3% (+22.0%/yr)KYMR compounded faster over this window
ARWR KYMR
ARWR vs KYMR: by the numbers
- •ARWR is the larger company ($8.69B vs $8.57B market cap).
- •Both run net losses; ARWR's is the smaller (-47.79% vs -285.41% net margin).
- •ARWR grew revenue faster over the past five years (44.14% vs 10.22% CAGR).
Metrics side by side
Valuation
| Metric | ARWR | KYMR |
|---|---|---|
| P/S ratio | 12.97 | 81.62 |
| P/B ratio | 18.66 | 5.68 |
Profitability
| Metric | ARWR | KYMR |
|---|---|---|
| Gross margin | 100.00% | 101.98% |
| Operating margin | 11.86% | -891.33% |
| Net margin | -47.79% | -285.41% |
| ROE | -68.73% | -19.85% |
| ROIC | -12.12% | -22.30% |
Growth (annualized)
| Metric | ARWR | KYMR |
|---|---|---|
| Revenue CAGR (5Y) | 44.14% | 10.22% |
| Total return CAGR (5Y) | 0.75% | 12.31% |
Frequently asked
- Which has grown faster, ARWR or KYMR?
- Over the past five years, ARWR grew revenue faster — ARWR at a 44.14% CAGR versus KYMR at 10.22%.
- How have ARWR and KYMR total returns compared?
- Over the past 5 years, ARWR delivered 0.75% and KYMR delivered 12.31% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Arrowhead Pharmaceuticals ROEKymera Therapeutics ROEArrowhead Pharmaceuticals operating marginKymera Therapeutics operating marginArrowhead Pharmaceuticals revenue growthKymera Therapeutics revenue growthArrowhead Pharmaceuticals free cash flowKymera Therapeutics free cash flow
Arrowhead Pharmaceuticals & Kymera Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.